Best Practices in the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Best Practices in the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Best Practices in the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Discover best practices for determining surgical versus nonsurgical approaches to tenosynovial giant cell tumor (TGCT).

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This activity reviews key factors for determining surgical and nonsurgical approaches to tenosynovial giant cell tumor (TGCT) and explores updates to clinical guidelines. Dr. William Tap and Dr. John Healey discuss what those guidelines mean for our patients and the management of adverse events in an up-beat debate.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    William Tap, MD
    Chief, Sarcoma Medical Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, NY 

    Consulting Fees: Blueprint, Daiichi Sankyo, Deciphera, Eli Lilly, EMDSoreno, NanoCarrier Co, Ltd.
    Stock Ownership: Atropos Therapeutics, Certis Oncology Solutions
    Royalty: Companion Diagnostics for CDK4 inhibitors
    Patent Holder: Companion Diagnostics for CDK4 inhibitors

    John H. Healey, MD, FACS
    Chief, Orthopedic Surgery
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Consulting Fees:  Daiichi Sankyo

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough MD, FAAFP has nothing to disclose.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify factors that determine the nonsurgical versus surgical management of TGCT within the framework of a multidisciplinary team
    • Develop strategies to monitor and manage nonsurgical, treatment-related adverse events in TGCT
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, surgical oncologists, orthopedic surgeons, rheumatologists, oncology and orthopedic nurse practitioners, physician assistants, and oncology nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free